We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Presents its Fragment Screening Technology at Two Key Conferences
News

Evotec Presents its Fragment Screening Technology at Two Key Conferences

Evotec Presents its Fragment Screening Technology at Two Key Conferences
News

Evotec Presents its Fragment Screening Technology at Two Key Conferences

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Presents its Fragment Screening Technology at Two Key Conferences"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG will be presenting at two conferences on its fragment screening technology. Presentations will be given at Screening, MedChem and ADMET Europe on 24th February in Berlin, Germany and at the Molecular Medicine Tri-Conference in San Francisco, USA on 25th February.

Evotec’s fragment screening platform, EVOlution™ combines ultra sensitive bioassay and high field NMR screening technologies with a highly diverse library of 40,000 fragments. By combining the two detection technologies with a large pool of diverse fragments Evotec can identify fragment hits against a range of targets including protein-protein interactions. During the conferences Evotec will illustrate the use of its technology in finding fragment hits for targets of high pharmaceutical interest.

During the Screening, MedChem and ADMET Europe conference in Berlin, Evotec will discuss the identification of novel MAPKAP Kinase 2 (MK2) Inhibitors and will also present a poster entitled, ‘Fragment-based Drug Discovery by NMR: Reaping the benefits of orthogonal screening approaches to validate hit compounds’.

At the Molecular Medicine Tri-Conference, Evotec will present on the use of its fragment screening technology to discover novel inhibitors for prominent targets, in particular PDE10a, BACE-1 and MK2.

Evotec will also be exhibiting two posters entitled, ‘The crystal structure of human phosphodiesterase 10a (hPDE10a) in complex with papaverine’; and ‘Identification of fragment inhibitors of phosphodiesterase 10a (PDE10a)’.
Advertisement